Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Dartmouth, Alcon, and More


Title: Determinants of Sensitivity to Chemotherapeutic Agents

Patent Number: 8,673,869

Filed: Dec. 14, 2005

Lead Inventor: Anna De Fazio, University of Sydney

Title: Method of Modulation of Expression of Epidermal Growth Factor Receptor Involving miRNA

Patent Number: 8,673,872

Filed: Aug. 28, 2007

Lead Inventor: Peter Leedman, University of Western Australia

Title: RNAi-mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-related Ocular Conditions

Patent Number: 8,673,873

Filed: Oct. 16, 2009

Lead Inventor: John Yanni, Alcon

Title: Methods for Treating Pancreatic Cancer

Patent Number: 8,673,874

Filed: Dec. 5, 2011

Inventor: Murray Korc, Dartmouth College

Title: Method for Treating Atherosclerosis

Patent Number: 8,673,875

Filed: Dec. 11, 2012

Lead Inventor: Suh-Hang Juo, Kaohsiung Medical University

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.